MULTIPLE MYELOMA

This study tested a combination of two drugs, ixazomib and daratumumab, without using steroids (dexamethasone) in elderly patients (65 and older) whose multiple myeloma had come back after previous treatment. The goal was to see if this approach could effectively control the dise…

This early-stage study tested a combination of two drugs, alnuctamab and mezigdomide, in people with multiple myeloma that had come back or stopped responding to treatment. The goal was to find the right dose and check safety. Only 4 people took part before the study was stopped …

This study tested a new treatment called LCAR-B38M CAR-T cells in 123 Chinese adults with multiple myeloma that had returned or not responded to at least three prior therapies. The treatment uses a patient's own immune cells, modified to target and kill cancer cells. The study ai…

This study looked at whether adding ixazomib to lenalidomide and dexamethasone can help control multiple myeloma in people who already received three cycles of bortezomib-based therapy. About 141 adults took part. The goal was to see how long the disease stayed under control. The…

This early-phase study tested whether the drug belantamab mafodotin (Blenrep) could help prevent multiple myeloma from returning after a stem cell transplant. Six participants with relapsed or refractory myeloma received the drug as maintenance therapy. The study focused on safet…

This early-stage study aimed to find a safe dose of a new drug called modakafusp alfa when used with other treatments for multiple myeloma, a type of blood cancer. The trial planned to enroll 15 adults who had already received a stem cell transplant. However, the study was termin…

This study tested a cell therapy called bb2121 (Ide-cel) combined with other drugs in adults with multiple myeloma that had returned or stopped responding to treatment. The goal was to find the best dose and check safety and effectiveness. The study was terminated early after enr…

This study looked at two different high-dose chemotherapy treatments given before a stem cell transplant in people aged 65 and older with multiple myeloma. The goal was to see if adding the drug bortezomib to the standard chemotherapy melphalan could help keep the cancer from com…

This study tested a new drug called CC-92480, alone or with dexamethasone, in people with multiple myeloma that returned or didn't respond to at least three prior treatments. The goal was to check safety, find the right dose, and see if it could shrink tumors. The trial was stopp…

This study tested an experimental drug called modakafusp alfa in people with multiple myeloma that had returned or stopped responding to other treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was stopped early, but the results help g…

This study looked at whether a donor stem cell transplant (allogeneic SCT) could help people with multiple myeloma whose cancer returned after initial treatment. It compared this approach to continuing standard drug therapy. The trial aimed to see if the transplant could improve …

This study tested a new drug (modakafusp alfa) combined with a standard treatment (daratumumab) in 15 people whose multiple myeloma had returned or stopped responding to prior therapies. The main goals were to check safety and find the best dose. The study was terminated early, s…

This study tested a new drug, elranatamab, combined with other cancer treatments for people with multiple myeloma that had returned or not responded to at least three prior therapies. The goal was to find the best dose and see if the combination helps control the disease. The stu…

This early-phase study tested a new type of immunotherapy called CAR-T cells, which are the patient's own immune cells modified to attack a protein called BCMA found on myeloma cells. The trial included adults with multiple myeloma that had not responded to at least two prior tre…

This study tested a combination of two immunotherapy drugs (nivolumab and ipilimumab) given after a stem cell transplant in people with high-risk multiple myeloma or lymphoma. The goal was to see if this approach is safe and can help prevent the cancer from coming back. The study…

This early-stage study tested a new drug called tasquinimod in people with multiple myeloma that had returned or stopped responding to treatment. The goal was to find a safe dose and see how well it worked, both alone and with standard therapies. The study was terminated early, s…

This study tested a new treatment called PHE885 for adults with multiple myeloma that had come back or stopped responding to at least three prior treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells. The study aimed to see how many patients' …

This study tested an experimental drug called INCB000928 in 22 people with anemia caused by myelodysplastic syndromes (MDS) or multiple myeloma. The goal was to find a safe dose and see if it could improve red blood cell counts. The trial was stopped early, so results are limited…

This study tested a sensory rehabilitation program for adults with blood cancers (like lymphoma or multiple myeloma) who had smell and taste problems after finishing chemotherapy. The program used special sprays and exercises to retrain the senses. Only 5 people enrolled before t…

This study was a registry that followed over 3,000 adults newly diagnosed with multiple myeloma to understand how the disease is managed in everyday medical practice. Researchers collected information on patient backgrounds, treatments, and outcomes without providing any new ther…

This study aimed to track four bone-related substances in the blood and urine of multiple myeloma patients treated with intravenous bisphosphonates (bone-strengthening drugs). Researchers wanted to see how these markers changed over 12 months. Only 3 patients were enrolled before…

This study looked at why some people with multiple myeloma develop shortness of breath when taking the drug carfilzomib. Researchers used an FDA-approved device to check blood vessel health and see if it relates to breathing problems. The goal was to better understand and prevent…